Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: mishedlo who wrote (268367)	11/21/2003 11:58:10 AM
From: S. maltophilia	Read Replies (1) \| Respond to of 436258

Why not? They have a cure for everything.<g> KEY FACTS Immtech International, Inc. is a pharmaceutical company focused on the development and commercialization of oral drugs to treat fungal, parasitic, bacterial and viral diseases. The Company has development programs that include fungal infections, malaria, tuberculosis, hepatitis C, pneumocystis carinii pneumonia and tropical medicine diseases, including African sleeping sickness (a parasitic disease also known as trypanosomiasis) and leishmaniasis (a parasitic disease that destroys the liver). One of its most significant research developments was the discovery of drug delivery technology to make dication drugs orally deliverable. This proprietary technology temporarily masks the positive charges of the dication, enabling the active compound to move easily across digestive membranes into blood circulation. Number of Employees 11 Sales (in millions) $1.61 1-Yr. Sales Change -54.32%